{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:34:04Z","timestamp":1791462844667,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":246,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100759","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:01:52Z","timestamp":1694167312000},"page":"100759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Rossella","family":"Lib\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-0845","authenticated-orcid":false,"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100759_bib0001","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0002","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0003","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0004","first-page":"1366","article-title":"American Association of Clinical Endocrinology Disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0006","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0007","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00261-018-1603-3","article-title":"Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical carcinomas on computed tomography","volume":"43","author":"Thomas","year":"2018","journal-title":"Abdom. Radiol. N. Y."},{"key":"10.1016\/j.ctarc.2023.100759_bib0008","doi-asserted-by":"crossref","first-page":"479.e17","DOI":"10.1016\/j.crad.2020.01.012","article-title":"Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma","volume":"75","author":"Ahmed","year":"2020","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0009","first-page":"1740","article-title":"Needle tract seeding following core biopsies in retroperitoneal sarcoma","volume":"43","author":"Van Houdt","year":"2017","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0010","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/PAS.0b013e31825a6308","article-title":"Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE","volume":"36","author":"Tissier","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0012","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/106689690401200304","article-title":"Adrenocortical oncocytic tumors: report of 10 cases and review of the literature","volume":"12","author":"Bisceglia","year":"2004","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0013","first-page":"1708","article-title":"For Comete-Cancer network, clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation","volume":"31","author":"Renaudin","year":"2018","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.ctarc.2023.100759_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.09.035","article-title":"Validation of the prognostic role of the \u201cHelsinki Score\u201d in 225 cases of adrenocortical carcinoma","volume":"62","author":"Duregon","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","article-title":"Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas","volume":"46","author":"Pennanen","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0016","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2023.100759_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","article-title":"Endocrine tumor board of Gustave Roussy, adrenocortical carcinoma","volume":"44","author":"Baudin","year":"2015","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.ctarc.2023.100759_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","article-title":"Prognostic parameters of metastatic adrenocortical carcinoma","volume":"92","author":"Assi\u00e9","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0022","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0023","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamaoncol.2019.1558","article-title":"Value of molecular classification for prognostic assessment of adrenocortical carcinoma","volume":"5","author":"Assi\u00e9","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American association of endocrine surgeons guidelines for adrenalectomy: executive summary","author":"Yip","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ctarc.2023.100759_bib0025","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1245\/s10434-018-6546-y","article-title":"Role of additional organ resection in adrenocortical carcinoma: analysis of 167 patients from the U.S. adrenocortical carcinoma database","volume":"25","author":"Marincola Smith","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0026","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"joint working group of ESES and ENSAT, European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ctarc.2023.100759_bib0027","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1245\/s10434-020-08824-9","article-title":"Implications of conversion during attempted minimally invasive adrenalectomy for adrenocortical carcinoma","volume":"28","author":"Delozier","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0028","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OTT.S157518","article-title":"Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis","volume":"11","author":"Zheng","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ctarc.2023.100759_bib0029","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jso.26418","article-title":"Reassessing the impact of tumor size on operative approach in adrenocortical carcinoma","volume":"123","author":"Hue","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e3182367ac3","article-title":"German ACC study group, Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma","volume":"255","author":"Reibetanz","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ctarc.2023.100759_bib0031","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1245\/s10434-017-6064-3","article-title":"The impact of nodal dissection on staging in adrenocortical carcinoma","volume":"24","author":"Panjwani","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0032","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1245\/s10434-016-5536-1","article-title":"Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit?","volume":"23","author":"Gerry","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0033","doi-asserted-by":"crossref","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","article-title":"Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients","volume":"5","author":"Terzolo","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.ctarc.2023.100759_bib0034","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"10.1016\/j.ctarc.2023.100759_bib0035","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2023.100759_bib0036","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0037","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0038","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1245\/s10434-018-6510-x","article-title":"Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma","volume":"25","author":"Nelson","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0039","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2023.100759_bib0040","doi-asserted-by":"crossref","first-page":"e6741","DOI":"10.1097\/MD.0000000000006741","article-title":"The efficacy of radiation therapy in adrenocortical carcinoma: A propensity score analysis of a population-based study","volume":"96","author":"Luo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctarc.2023.100759_bib0041","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12672-020-00385-3","article-title":"Advanced Adrenocortical Carcinoma (ACC): a review with focus on second-line therapies","volume":"11","author":"Ardolino","year":"2020","journal-title":"Horm. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0043","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0044","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2023.100759_bib0045","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1530\/EC-18-0428","article-title":"Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study","volume":"7","author":"Jouinot","year":"2018","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ctarc.2023.100759_bib0046","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr. Relat. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0047","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0048","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0049","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0050","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0051","doi-asserted-by":"crossref","first-page":"dgz318","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0052","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0053","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0054","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0056","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctarc.2023.100759_bib0057","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.ctarc.2023.100759_bib0058","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.2006.02576.x","article-title":"Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma","volume":"65","author":"Papewalis","year":"2006","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"10.1016\/j.ctarc.2023.100759_bib0059","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work?","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2023.100759_bib0060","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2022.40.16_suppl.4596","article-title":"EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study","volume":"40","author":"Baudin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100759_bib0061","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2011-2765","article-title":"[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma","volume":"97","author":"Hahner","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2023.100759_bib0062","doi-asserted-by":"crossref","first-page":"dgz091","DOI":"10.1210\/clinem\/dgz091","article-title":"Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors","volume":"105","author":"Grisanti","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:22:30Z","timestamp":1722957750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":62,"alternative-id":["S2468294223000813"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100759","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100759"}}